

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(於開曼群島註冊成立之有限公司)

(股份代號：8158)

截至二零二六年六月三十日止六個月之 中期業績公告

中國再生醫學國際有限公司(「**本公司**」)董事(「**董事**」)會(「**董事會**」)謹此宣佈本公司及其附屬公司(統稱「**本集團**」)截至二零二六年六月三十日止六個月之未經審核簡明綜合中期業績。本公告列載本公司二零二六年中期報告(「**中期報告**」)之全文，並符合香港聯合交易所有限公司GEM證券上市規則(「**GEM上市規則**」)中有關中期業績初步公告附載的資料的相關規定。中期報告將於適當時候於聯交所網站www.hkexnews.hk及本公司網站www.crimi.hk可供審閱。

承董事會命

中國再生醫學國際有限公司

主席、行政總裁及執行董事

王闖

香港，二零二六年八月二十一日

於本公告日期，執行董事為王闖先生(主席兼行政總裁)；非執行董事為雒敏女士；以及獨立非執行董事為霍春玉女士、周旭東先生及梁文輝先生。

本公告的資料乃遵照GEM上市規則而刊載，旨在提供有關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。董事在作出一切合理查詢後，確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤導。

本公告將由刊發日期起計最少一連七日保留於GEM網站www.hkexnews.hk之「最新上市公司公告」一頁及於本公司之網站www.crimi.hk內登載。

CHARACTERISTICS OF GEM (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the “Directors”) of China Regenerative Medicine International Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company and its subsidiaries (collectively the “Group”). The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特點

GEM之定位乃為相比其他在聯交所上市之公司帶有較高投資風險之中小型公司提供一個上市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決定。

由於GEM上市之公司普遍為中小型公司，在GEM買賣之證券可能會較在主板買賣之證券承受較大之市場波動風險，同時無法保證在GEM買賣之證券會有高流通量之市場。

香港交易及結算有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本報告全部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。

本報告旨在遵照聯交所GEM證券上市規則（「GEM上市規則」）之規定，提供有關中國再生醫學國際有限公司（「本公司」）及其附屬公司（統稱為「本集團」）之資料。本公司董事（「董事」）對此共同及個別承擔全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何其他事項，足以令致本報告或其所載任何陳述產生誤導。

CONTENTS

目錄

Corporate Information	公司資料	3
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	簡明綜合損益及 其他全面收入表	6
Condensed Consolidated Statement of Financial Position	簡明綜合財務狀況表	8
Condensed Consolidated Statement of Changes in Equity	簡明綜合權益變動表	10
Condensed Consolidated Statement of Cash Flows	簡明綜合現金流量表	12
Notes to the Condensed Consolidated Financial Statements	簡明綜合財務報表附註	13
Management Discussion and Analysis	管理層討論及分析	26
Other Information	其他資料	31

In the event of any error or omission in the Chinese translation of this interim report, the English text shall prevail.

本中期報告之中文翻譯如有任何錯漏，應以英文為準。

CORPORATE INFORMATION

公司資料

DIRECTORS

Executive Director

Mr. Wang Chuang (*Chairman of the Board and Chief Executive Officer*)

Non-executive Director

Ms. Luo Min

Independent Non-executive Directors

Mr. Leung Man Fai

Ms. Huo Chunyu

Mr. Zhou Xudong

COMPANY SECRETARY

Ms. Chan Lok Tung

NOMINATION COMMITTEE

Mr. Zhou Xudong (*Chairman*)

Mr. Leung Man Fai

Ms. Huo Chunyu

REMUNERATION COMMITTEE

Mr. Zhou Xudong (*Chairman*)

Ms. Huo Chunyu

Mr. Leung Man Fai

AUDIT COMMITTEE

Mr. Leung Man Fai (*Chairman*)

Ms. Huo Chunyu

Mr. Zhou Xudong

董事

執行董事

王闖先生 (董事會主席兼行政總裁)

非執行董事

雒敏女士

獨立非執行董事

梁文輝先生

霍春玉女士

周旭東先生

公司秘書

陳樂彤女士

提名委員會

周旭東先生 (主席)

梁文輝先生

霍春玉女士

薪酬委員會

周旭東先生 (主席)

霍春玉女士

梁文輝先生

審核委員會

梁文輝先生 (主席)

霍春玉女士

周旭東先生

REGISTERED OFFICE

Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Suite 2310–2318, Miramar Tower
132 Nathan Road
Tsim Sha Tsui, Kowloon
Hong Kong

COMPLIANCE OFFICER

Mr. Wang Chuang

AUTHORISED REPRESENTATIVES

Mr. Wang Chuang
Ms. Chan Lok Tung

PRINCIPAL BANKERS

Hong Kong and Shanghai Banking Corporation Limited
Hang Seng Bank Limited
Dah Sing Bank Limited
Jiangnan Rural Commercial Bank
Industrial and Commercial Bank of China
Bank of China (Hong Kong) Limited

AUDITOR

Linkfield CPA Limited
Certified Public Accountants
Registered Public Interest Entity Auditor
Unit 3606, 36/F, China Resources Building
26 Harbour Road
Wanchai
Hong Kong

註冊辦事處

Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

總辦事處及香港 主要營業地點

香港
九龍尖沙咀
彌敦道132號
美麗華大廈2310–2318室

合規主任

王闖先生

授權代表

王闖先生
陳樂彤女士

主要往來銀行

香港上海滙豐銀行有限公司
恒生銀行有限公司
大新銀行有限公司
江南農村商業銀行
中國工商銀行
中國銀行(香港)有限公司

核數師

金道連城會計師事務所有限公司
執業會計師
註冊公眾利益實體核數師
香港
灣仔
港灣道26號
華潤大廈36樓3606室

LEGAL ADVISERS

As to Cayman Islands laws:
Conyers Dill & Pearman
29th Floor, One Exchange Square
8 Connaught Place, Central
Hong Kong

As to Hong Kong laws:
Charles Wilson LLP
Unit 1601, 100 QRC
Queen's Road Central, Central
Hong Kong

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Conyers Trust Company
(Cayman) Limited
Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Union Registrars Limited
Suites 3301-04, 33/F.
Two Chinachem Exchange Square
338 King's Road, North Point
Hong Kong

COMPANY WEBSITE

www.crmi.hk

STOCK CODE

8158

法律顧問

有關開曼群島法律：
Conyers Dill & Pearman
香港
中環康樂廣場8號
交易廣場第一座29樓

有關香港法律：
樂偉舜律師事務所
香港
中環皇后大道中100號
100QRC 1601室

開曼群島股份 過戶登記總處

Conyers Trust Company
(Cayman) Limited
Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

香港股份 過戶登記分處及 股份過戶辦事處

聯合證券登記有限公司
香港
北角英皇道338號
華懋交易廣場2期
33樓3301-04室

公司網址

www.crmi.hk

股份代號

8158

The board of Directors (the “Board”) of the Company hereby announces the unaudited condensed consolidated result of the Group for the six months ended 30 June 2026, together with the comparative unaudited figures for the corresponding period in 2025 as follows:

本公司董事會（「董事會」）謹此公佈本集團截至二零二六年六月三十日止六個月之未經審核簡明綜合業績，連同二零二五年同期之未經審核比較數字如下：

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

簡明綜合損益及其他全面收入表

For the six months ended 30 June 2026
截至二零二六年六月三十日止六個月

			Six months ended 30 June 截至六月三十日止六個月	
			2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
		Notes 附註		
Revenue	收益	3	41,734	27,391
Cost of sales	銷售成本		(17,418)	(9,509)
Gross Profit	毛利		24,316	17,882
Other income, gain and loss	其他收入、收益及虧損	3	235	8,338
Selling and distribution expenses	銷售及分銷開支		(2,752)	(2,361)
Administrative and other expenses	行政及其他開支		(17,372)	(15,233)
Finance costs	財務費用	5	(1,063)	(657)
Reversal/(provision) of expected credit loss of other receivables	其他應收賬項的預期信貸虧損撥回／（撥備）		1,259	(3,360)
Profit before tax	除稅前溢利	6	4,623	4,609
Income tax expense	所得稅開支	7	—	—
Profit for the period attributable to equity holders of the Company	本公司權益持有人應佔期內溢利		4,623	4,609

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Continued)

簡明綜合損益及其他全面收入表 (續)

For the six months ended 30 June 2026
截至二零二六年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Notes 附註			
	Other comprehensive loss 其他全面虧損		
	<i>Item that may be reclassified subsequently to profit or loss:</i> <i>其後可能重新分類至損益之項目：</i>		
	Exchange loss on translation of financial statements of foreign operations 換算海外業務財務報表之匯兌虧損	(1,341)	(742)
	Other comprehensive loss for the period 期內其他全面虧損	(1,341)	(742)
	Total comprehensive income for the period attributable to the equity holders of the Company 本公司權益持有人應佔期內全面總收入	3,282	3,867
	Earnings per share attributable to equity holders of the Company: 歸屬於本公司權益持有人之每股盈利：		
	– Basic (HK cents) 一基本 (港仙)	1.51	1.51
	– Diluted (HK cents) 一攤薄 (港仙)	1.51	1.51

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

簡明綜合財務狀況表

As at 30 June 2026

於二零二六年六月三十日

		30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
	Notes 附註		
Non-current assets	非流動資產		
Property, plant and equipment	物業、廠房及設備	1,928	2,244
Right-of-use assets	使用權資產	16,576	20,900
Other receivables	其他應收賬項	30,139	58,878
		48,643	82,022
Current assets	流動資產		
Inventories	存貨	2,614	2,034
Trade receivables	應收貿易賬項	5,284	5,095
Deposits, prepayments and other receivables	按金、預付款項及其他應收賬項	84,875	70,739
Cash and bank balances	現金及銀行結餘	1,820	8,169
		94,593	86,037

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Continued) 簡明綜合財務狀況表 (續)

As at 30 June 2026
於二零二六年六月三十日

		Notes 附註	30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
Current liabilities	流動負債			
Trade payables	應付貿易賬項	11	4,346	3,003
Accruals and other payables	應計費用及 其他應付賬項		17,104	20,296
Contract liabilities	合約負債		12,922	26,661
Lease liabilities	租賃負債		8,677	8,464
Shareholders' loans	股東貸款		3,629	3,629
Current tax liabilities	當期稅項負債		13,714	13,172
			60,392	75,225
Net current assets	淨流動資產		34,201	10,812
Total assets less current liabilities	總資產減流動負債		82,844	92,834
Non-current liabilities	非流動負債			
Lease liabilities	租賃負債		8,344	12,736
Shareholders' loan	股東貸款		17,597	26,477
Deferred tax liabilities	遞延稅項負債		147	147
			26,088	39,360
NET ASSETS	淨資產		56,756	53,474
Capital and reserves	資本及儲備			
Share capital	股本	12	60,850	60,850
Reserves	儲備		(4,094)	(7,376)
TOTAL EQUITY	總權益		56,756	53,474

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

簡明綜合權益變動表

For the six months ended 30 June 2026
截至二零二六年六月三十日止六個月

		Share capital 股本 HK\$'000	Share premium 股份溢價 HK\$'000	Translation reserve 換算儲備 HK\$'000	Special reserve 特殊儲備 HK\$'000 千港元 (Note (i)) (附註(i))	Other reserve 其他儲備 HK\$'000 千港元 (Note (ii)) (附註(ii))	Share option reserve 購股權儲備 HK\$'000	Accumulated losses 累計虧損 HK\$'000	Total 合計 HK\$'000
		千港元	千港元	千港元			千港元	千港元	千港元
At 1 January 2025 (audited)	於二零二五年一月一日 (經審核)	60,850	3,215,749	(15,537)	(200)	(413,100)	40,609	(2,863,174)	25,197
Comprehensive income	全面收入								
Profit for the period	期內溢利	-	-	-	-	-	-	4,609	4,609
Other comprehensive loss	其他全面虧損								
Exchange differences arising on translation of foreign operations	換算海外業務導致的 匯兌差異	-	-	(742)	-	-	-	-	(742)
Total comprehensive income/ (loss) for the period	期內全面總收入/ (虧損)	-	-	(742)	-	-	-	4,609	3,867
At 30 June 2025 (unaudited)	於二零二五年六月三十日 (未經審核)	60,850	3,215,749	(16,279)	(200)	(413,100)	40,609	(2,858,565)	29,064

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Continued) 簡明綜合權益變動表(續)

For the six months ended 30 June 2026
截至二零二六年六月三十日止六個月

		Share capital 股本 HK\$'000	Share premium 股份溢價 HK\$'000	Translation reserve 換算儲備 HK\$'000	Special reserve 特殊儲備 HK\$'000 千港元 (Note (i)) (附註(i))	Other reserve 其他儲備 HK\$'000 千港元 (Note (ii)) (附註(ii))	Share option reserve 購股權儲備 HK\$'000	Accumulated losses 累計虧損 HK\$'000	Total 合計 HK\$'000
		千港元	千港元	千港元	千港元 (Note (i)) (附註(i))	千港元 (Note (ii)) (附註(ii))	千港元	千港元	千港元
At 1 January 2026 (audited)	於二零二六年一月一日 (經審核)	60,850	3,215,749	(14,785)	(200)	(413,100)	-	(2,795,040)	53,474
Comprehensive income	全面收入								
Profit for the period	期內溢利	-	-	-	-	-	-	4,623	4,623
Other comprehensive loss	其他全面虧損								
Exchange differences arising on translation of foreign operations	換算海外業務導致的 匯兌差異	-	-	(1,341)	-	-	-	-	(1,341)
Total comprehensive income/ (loss) for the period	期內全面總收入/ (虧損)	-	-	(1,341)	-	-	-	4,623	3,282
At 30 June 2026 (unaudited)	於二零二六年六月三十日 (未經審核)	60,850	3,215,749	(16,126)	(200)	(413,100)	-	(2,790,417)	56,756

Notes:

附註：

- (i) The special reserve represents the difference between the nominal value of the shares of the acquired subsidiaries and the nominal value of the Company's shares issued for their acquisition at the time of the Group's reorganisation in 2001.
- (ii) The other reserve represents (i) the difference between the fair value of consideration paid to increase the shareholding in subsidiaries and the amount of adjustment to noncontrolling interest; and (ii) deemed capital contribution from shareholders, represented the difference between the principal amount of the shareholders' loan and its fair value. The fair value is determined by discounting the estimate future cash flows throughout the expected life of the repayment.

- (i) 特殊儲備指本集團於二零零一年重組時，被收購附屬公司股份面值與本公司就收購該等附屬公司而予以發行之股份面值之差額。

- (ii) 其他儲備指(i)就增加於附屬公司之股權所付代價之公平值與非控股股東權益調整金額之差額；及(ii)視作股東注資指股東貸款本金額與其公平值之間的差額。公平值按整個預期償還期間貼現估計未來現金流量釐定。

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

上述簡明綜合權益變動表應與隨附附註一併閱讀。

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

簡明綜合現金流量表

For the six months ended 30 June 2026
截至二零二六年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Net cash used in operating activities	經營活動耗用現金淨額	(3,944)	(15,473)
Net cash generated from investing activities	投資活動所得現金淨額	–	1
Net cash (used in) financing activities	融資活動 (耗用) 現金淨額	(1,063)	(3,275)
Net decrease in cash and cash equivalents	現金及現金等值項目之減少淨額	(5,007)	(18,747)
Effect of foreign exchange rate changes, net	外匯匯率變動影響淨額	(1,342)	3,327
Cash and cash equivalents at the beginning of the period	期初之現金及現金等值項目	8,169	22,702
Cash and cash equivalents at the end of the period, represented by cash and bank balances	期末之現金及現金等值項目，指現金及銀行結餘	1,820	7,282

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

簡明綜合財務報表附註

Notes:

附註：

1. GENERAL INFORMATION

The Company was incorporated as an exempted company with limited liability in the Cayman Islands under the Companies Law (Revision 2001) of Cayman Islands on 20 April 2001. The address of the Company's registered office is Cricket Square, Hutchins Drive, P.O. Box 2861, Grand Cayman, KY1-1111, Cayman Islands and its principal place of business is situated at Suite 2310-2318, Miramar Tower, 132 Nathan Road, Tsim Sha Tsui, Kowloon, Hong Kong.

The Company's shares are listed on GEM of the Stock Exchange. The Company is an investment holding company. The principal activities of its subsidiaries are the provision of (i) aesthetic medical and beauty services; and (ii) medical services.

The unaudited condensed consolidated interim financial statements are presented in Hong Kong dollars ("HK\$"), which is the same as the functional currency of the Group.

2. BASIS OF PREPARATION

These unaudited condensed consolidated interim financial statements have been prepared in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" ("HKAS 34") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and the applicable disclosure provisions of the GEM Listing Rules.

The preparations of these unaudited condensed consolidated interim financial statements in compliance with HKAS 34 requires the use of certain judgements, estimates and assumptions that affect the application of policies and the reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

1. 一般資料

本公司於二零零一年四月二十日根據開曼群島公司法(二零零一年修訂版)在開曼群島註冊成立為獲豁免有限公司。本公司註冊辦事處及主要營業地點之地址分別為Cricket Square, Hutchins Drive, P.O. Box 2861, Grand Cayman, KY1-1111, Cayman Islands及香港九龍尖沙咀彌敦道132號美麗華大廈2310-2318室。

本公司股份於聯交所GEM上市。本公司為一間投資控股公司。其附屬公司的主要業務為提供(i)美學醫療及美容服務；及(ii)醫療服務。

未經審核簡明綜合中期財務報表以本集團之功能貨幣港元(「港元」)呈列。

2. 編製基準

該等未經審核簡明綜合中期財務報表乃根據香港會計師公會(「香港會計師公會」)頒佈的香港會計準則第34號「中期財務報告」(「香港會計準則第34號」)及GEM上市規則的適用披露規定而編製。

編製符合香港會計準則第34號的該等未經審核簡明綜合中期財務報表需要使用若干判斷、估計及假設，而有關判斷、估計及假設會影響政策之應用以及按年初至今基準計算之資產與負債、收入及開支之呈報金額。實際結果可能與該等估計有所不同。

2. BASIS OF PREPARATION (Continued)

These unaudited condensed consolidated interim financial statements do not include all the information and disclosures required in a full set of financial statements prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs"), and should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2025 (the "2025 Annual Financial Statements").

These unaudited condensed consolidated interim financial statements have been prepared with the same accounting policies adopted in the 2025 Annual Financial Statements, except for those that relate to new standards or interpretations effective for the first time for periods beginning on or after 1 January 2026. The adoption of these new or revised HKFRSs has had no material effect on the amounts reported and/or disclosures set out in these unaudited condensed consolidated interim financial statements. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

These unaudited condensed consolidated interim financial statements of the Group have not been audited, but have been reviewed by the audit committee of the Company (the "Audit Committee").

2. 編製基準 (續)

該等未經審核簡明綜合中期財務報表並未包含根據香港財務報告準則（「香港財務報告準則」）編製的完整財務報表所需的所有資料及披露，應與本集團截至二零二五年十二月三十一日止年度之年度財務報表（「二零二五年年度財務報表」）一併閱覽。

編製該等未經審核簡明綜合中期財務報表所用之會計政策與二零二五年年度財務報表所採納者相同（與於二零二六年一月一日或之後開始的期間首次生效的新訂準則或詮釋相關者除外）。採納該等新訂或經修訂香港財務報告準則並無對該等未經審核簡明綜合中期財務報表所呈報的金額及／或所載披露造成重大影響。本集團並無提早採納已頒佈但尚未生效的任何其他準則、詮釋或修訂。

本集團的該等未經審核簡明綜合中期財務報表乃未經審核，但已經本公司審核委員會（「審核委員會」）審閱。

3. REVENUE AND OTHER INCOME, GAIN AND LOSS

(a) Revenue

The Group's revenue represents the aggregate of invoiced value of goods sold and services provided during the periods, analysed as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Revenue recognised upon provision of services:	於提供服務後已確認收益：		
At a point in time	時間點	9,175	8,940
Over time	時間段	32,559	18,451
		41,734	27,391

(b) Other income, gain and loss

An analysis of other income, gain and loss recognised is as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Bank interest income	銀行利息收入	–	1
Others	其他	235	240
Interest accretion on other receivables	其他應收款項的利息增加	–	8,097
		235	8,338

3. 收益及其他收入、收益及虧損

(a) 收益

本集團的收益指期內已售商品及已提供服務的發票總價值，分析如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Revenue recognised upon provision of services:	於提供服務後已確認收益：		
At a point in time	時間點	9,175	8,940
Over time	時間段	32,559	18,451
		41,734	27,391

(b) 其他收入、收益及虧損

其他收入、收益及虧損分析如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Bank interest income	銀行利息收入	–	1
Others	其他	235	240
Interest accretion on other receivables	其他應收款項的利息增加	–	8,097
		235	8,338

4. SEGMENT INFORMATION

The Group identifies operating segments and prepares segment information based on the regular internal financial information reported to the executive Director, being the Chief Operating Decision Maker ("CODM") of the Group, for his decisions about resources allocation to the Group's business components and for his review of the performance of those components. The business components in the internal financial information reported to the executive Director are determined based on the Group's major product and service lines.

The Group has identified the following operating and reportable segments:

- Aesthetic medical and beauty services, including the provision of medical beauty products and services
- Medical services, including the provision of medical products and services

The measurement policies used by the Group for reporting segment results under HKFRS 8 are the same as those used in its financial statements prepared under HKFRSs, except that:

- certain finance costs
- income tax
- corporate income and expenses which are not directly attributable to the business activities of any operating segment

are not included in arriving the operating results of the operating segments.

4. 分部資料

本集團根據向執行董事（即本集團主要經營決策者（「主要經營決策者」））呈報以供其決定本集團各業務成分的資源分配及評核該等成分表現的定期內部財務資料，確認經營分部及編製分部資料。向執行董事呈報的內部財務資料內的業務成分乃依據本集團主要產品及服務分支確定。

本集團已識別下列經營及可呈報分部：

- 美學醫療及美容服務，包括提供醫療美容產品及服務
- 醫療服務，包括提供醫療產品及服務

本集團根據香港財務報告準則第8號就報告分部業績所採用的計量政策，與根據香港財務報告準則編製其財務報表所採用的相同，惟以下各項：

- 若干財務費用
- 所得稅
- 並非直接歸屬於任何經營分部之業務活動的企業收入及開支

於計算經營分部的經營業績時並不包括在內。

4. SEGMENT INFORMATION (Continued)

Segment revenue and results

		Aesthetic medical and beauty services 美學醫療及 美容服務 HK\$'000 千港元 Unaudited 未經審核	Medical services 醫療服務 HK\$'000 千港元 Unaudited 未經審核	Total 總計 HK\$'000 千港元 Unaudited 未經審核
For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月				
External sales and revenue	對外銷售及收入	37,144	4,590	41,734
Segment profit/(losses)	分部溢利／(虧損)	19,576	(1,438)	18,138
Unallocated corporate income	未分配企業收入			235
Unallocated corporate expenses	未分配企業開支			(12,687)
Finance costs	財務費用			(1,063)
Group's profit before tax	本集團稅前溢利			4,623

		Aesthetic medical and beauty services 美學醫療及 美容服務 HK\$'000 千港元 Unaudited 未經審核	Medical services 醫療服務 HK\$'000 千港元 Unaudited 未經審核	Total 總計 HK\$'000 千港元 Unaudited 未經審核
For the six months ended 30 June 2025 截至二零二五年六月三十日止六個月				
External sales and revenue	對外銷售及收入	24,160	3,231	27,391
Segment profit/(losses)	分部溢利／(虧損)	13,559	(1,101)	12,458
Unallocated corporate income	未分配企業收入			240
Unallocated corporate expenses	未分配企業開支			(8,046)
Finance costs	財務費用			(43)
Group's profit before tax	本集團稅前溢利			4,609

Unallocated corporate expenses mainly included staff costs, exchange loss, rental and other expenses not directly attributable to the business activities of any operating segments.

未分配企業開支主要包括非直接由任何經營分部之業務活動產生的員工成本、匯兌虧損、租金及其他開支。

4. SEGMENT INFORMATION (Continued)

4. 分部資料 (續)

		30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
Assets	資產		
Reportable segment assets	須予呈報分部資產		
– aesthetic medical and beauty services	– 美學醫療及美容服務	135,213	129,292
Reportable segment assets	須予呈報分部資產		
– medical services	– 醫療服務	5,229	3,516
Cash and bank balances	現金及銀行結餘	1,820	8,169
Other corporate assets	其他企業資產	974	27,082
Group assets	集團資產	143,236	168,059
Liabilities	負債		
Reportable segment liabilities	須予呈報分部負債		
– aesthetic medical and beauty services	– 美學醫療及美容服務	26,308	44,659
Reportable segment liabilities	須予呈報分部負債		
– medical services	– 醫療服務	16,779	16,276
Shareholders' loans	股東貸款	21,226	30,106
Deferred tax liabilities	遞延稅項負債	147	147
Lease liabilities	租賃負債	17,021	21,200
Other corporate liabilities	其他企業負債	4,999	2,197
Group liabilities	集團負債	86,480	114,585

4. SEGMENT INFORMATION (Continued)

The geographical location of revenue from customers is based on the location at which the services were provided or the goods delivered.

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Hong Kong	香港	38,506	27,089
The People's Republic of China ("PRC")	中華人民共和國 (「中國」)	3,228	302
		41,734	27,391

5. FINANCE COSTS

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Interest on lease liabilities	租賃負債利息	467	45
Interest expenses on shareholders' loans	股東貸款利息開支	596	612
		1,063	657

4. 分部資料 (續)

客戶收益所在地點乃根據所提供之服務或交付貨品之地點劃分。

5. 財務費用

6. PROFIT BEFORE TAX

Profit before tax is arrived at after charging:

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Depreciation for property, plant and equipment	物業、廠房及設備折舊	317	330
Depreciation of right-of-use assets	使用權資產折舊	4,324	3,989
Advertising and marketing, included in selling and distribution expenses	廣告及市場推廣，計入銷售及分銷開支	1,627	437
Cost of inventories sold	已售存貨成本	1,425	1,831
Employee benefit expenses (including Directors' emoluments)	僱員福利開支 (包括董事酬金)	6,089	6,297

7. INCOME TAX EXPENSE

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Current tax	當期稅項	—	—
Deferred tax charge	遞延稅項支出	—	—
		—	—

Under Hong Kong's two-tiered profits tax regime, the first HK\$2 million of profits of the qualifying group entity established in Hong Kong will be taxed at 8.25%, and profits above that amount will be subject to the tax rate of 16.5%. The profits of the group entities not qualifying for the two-tiered profit tax rate regime will continue to be taxed at a rate of 16.5%. The Group's subsidiaries operating in the PRC are subject to PRC Enterprise Income Tax ("EIT") at the rate of 25% on the assessable profits of the subsidiaries.

6. 除稅前溢利

除稅前溢利已扣除下列各項：

Six months ended 30 June
截至六月三十日止六個月

2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
317	330
4,324	3,989
1,627	437
1,425	1,831
6,089	6,297

7. 所得稅開支

Six months ended 30 June
截至六月三十日止六個月

2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
—	—
—	—
—	—

根據香港兩級制利得稅制度，於香港成立的合資格集團實體的首2,000,000港元溢利將按8.25%稅率徵稅，而超過該數額之溢利將以16.5%的稅率徵稅。不符合利得稅兩級制之集團實體的溢利將繼續按16.5%的稅率徵稅。本集團於中國經營的附屬公司按其應課稅溢利的25%繳納中國企業所得稅（「企業所得稅」）。

7. INCOME TAX EXPENSE (Continued)

Certain PRC subsidiaries which qualify as small and low-profit enterprises are eligible for a preferential EIT rate of 5%.

No provision for PRC EIT has been provided for the six months ended 30 June 2026 as the Group did not generate any assessable profits in PRC during the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

No provision for Hong Kong profits tax has been provided for the six months ended 30 June 2026, as the Group has sufficient tax losses brought forward to set off against assessable profits in Hong Kong (six months ended 30 June 2025: the Group did not generate any assessable profits in Hong Kong).

8. DIVIDENDS

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

9. EARNINGS PER SHARE

Earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the six months ended 30 June 2026 and 2025.

7. 所得稅開支(續)

部分符合條件的中國附屬公司作為小型微利企業，可適用5%的企業所得稅優惠稅率。

截至二零二六年六月三十日止六個月，本集團並無就中國企業所得稅作出撥備，原因為本集團於截至二零二六年六月三十日止六個月並無於中國產生任何應課稅溢利（截至二零二五年六月三十日止六個月：無）。

截至二零二六年六月三十日止六個月，由於本集團有足夠的稅務虧損可供撥作抵銷香港的應課稅溢利，故並無就香港利得稅作出撥備（截至二零二五年六月三十日止六個月：本集團並無在香港產生任何應課稅溢利）。

8. 股息

董事會並不建議派付截至二零二六年六月三十日止六個月之中期股息（截至二零二五年六月三十日止六個月：無）。

9. 每股盈利

每股盈利乃按歸屬於本公司權益持有人之溢利除以截至二零二六年及二零二五年六月三十日止六個月已發行普通股加權平均數計算。

Six months ended 30 June 截至六月三十日止六個月

		2026 二零二六年 HK Cents 港仙 Unaudited 未經審核	2025 二零二五年 HK Cents 港仙 Unaudited 未經審核
Basic earnings per share attributable to equity holders of the Company	歸屬於本公司權益持有人之每股基本盈利	1.51	1.51
Diluted earnings per share attributable to equity holders of the Company	歸屬於本公司權益持有人之每股攤薄盈利	1.51	1.51

9. EARNINGS PER SHARE (Continued)

9. 每股盈利 (續)

Six months ended 30 June
截至六月三十日止六個月

		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Profit attributable to equity holders of the Company used in calculating basic earnings per share	計算每股基本盈利時所用之歸屬於本公司權益持有人之溢利	4,623	4,609
Weighted average number of ordinary shares in issue ('000)	已發行普通股加權平均數 (千股)	304,252	304,252

The diluted numbers of ordinary shares used as denominators in calculating the basic and diluted earnings per share are the same as there were no potential dilutive ordinary shares during the six months ended 30 June 2026 and 2025.

於計算每股基本及攤薄盈利時作為分母的普通股攤薄數目相同，原因為截至二零二六年及二零二五年六月三十日止六個月內並無潛在攤薄普通股。

10. TRADE RECEIVABLES, DEPOSITS,
PREPAYMENTS AND OTHER RECEIVABLES

10. 應收貿易賬項、按金、預付
款項及其他應收賬項

		30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
Trade receivables	應收貿易賬項		
Trade receivables	應收貿易賬項	5,284	5,095
Deposits, prepayments and other receivables	按金、預付款項及 其他應收賬項		
Rental deposit	租賃按金	5,706	5,706
Other deposits	其他按金	1,314	1,316
Prepayments to suppliers	支付予供應商的 預付款項	10,497	10,480
Other prepayments	其他預付款項	814	256
Other receivables, net of impairment losses recognised	其他應收賬項 (扣除 已確認減值虧損)	96,683	111,859
		115,014	129,617

The following is an aging analysis of trade receivables net of impairment losses recognised presented based on invoice date:

應收貿易賬項 (扣除已確認減值虧損) 按發票日期呈列的賬齡分析如下：

		30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
0-90 days	0至90天	5,281	4,640
91-180 days	91至180天	3	319
181-270 days	181至270天	-	104
271-360 days	271至360天	-	14
Over 360 days	超過360天	-	18
		5,284	5,095

The Group allows an average credit period of 60-180 days (31 December 2025: 0-180 days) to its customers.

本集團給予其客戶之平均信貸期為60至180天 (二零二五年十二月三十一日：0至180天)。

11. TRADE PAYABLES

		30 June 2026 二零二六年 六月三十日 HK\$'000 千港元 Unaudited 未經審核	31 December 2025 二零二五年 十二月三十一日 HK\$'000 千港元 Audited 經審核
0–30 days	0至30天	698	1,914
31–60 days	31至60天	–	880
61–90 days	61至90天	–	54
91–120 days	91至120天	3,648	140
121–150 days	121至150天	–	15
		4,346	3,003

Average credit period granted by suppliers to the Group are 30–60 days (31 December 2025: 30–60 days).

供應商授予本集團的平均信貸期介乎30至60天（二零二五年十二月三十一日：30至60天）。

12. SHARE CAPITAL

12. 股本

		Number of shares 股份數目	Nominal value 面值 HK\$'000 千港元
Authorised:	法定：		
At 31 December 2025, 1 January 2026 and 30 June 2026, ordinary shares of HK\$0.20 each	於二零二五年十二月三十一日、 二零二六年一月一日及 二零二六年六月三十日， 每股面值0.20港元的普通股	5,000,000,000	1,000,000
Issued and fully paid:	已發行及繳足：		
At 31 December 2025, 1 January 2026, and 30 June 2026, ordinary shares of HK\$0.20 each	於二零二五年十二月三十一日、 二零二六年一月一日及 二零二六年六月三十日， 每股面值0.20港元的普通股	304,252,480	60,850

13. RELATED PARTY TRANSACTIONS

In addition to the transactions detailed elsewhere in these unaudited condensed consolidated interim financial statements, the Group had the following transactions with related parties during the six months ended 30 June 2026 and 2025.

Compensation of key management personnel

The remuneration of the key management (excluding the Directors) was as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 HK\$'000 千港元 Unaudited 未經審核	2025 二零二五年 HK\$'000 千港元 Unaudited 未經審核
Salaries and other benefit	薪金及其他福利	476	702
Retirement benefits scheme contributions	退休福利計劃供款	9	9
		485	711

14. EVENTS AFTER THE REPORTING PERIOD

There was no significant event affecting the Group after the reporting period up to the date of this report.

13. 關聯方交易

除此等未經審核簡明綜合中期財務報表其他部分詳述的交易外，於截至二零二六年及二零二五年六月三十日止六個月，本集團有以下關聯方交易。

主要管理人員薪酬

主要管理人員（除董事外）的薪酬如下：

14. 報告期後事項

於報告期後直至本報告日期，概無發生影響本集團的重大事項。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

BUSINESS REVIEW AND FUTURE PROSPECT

During the interim period under review, cross-border travel between Hong Kong and Mainland China remained stable. Nevertheless, the market recovery for discretionary-spending sectors proceeded at an uneven pace. Affected by cautious consumer sentiment across the region, the Group's business did not register the anticipated growth and saw moderating operational momentum during the period.

Notwithstanding the relative improvement in Hong Kong's overall operating landscape, the retail and service industries continued to encounter headwinds brought about by shifting consumption patterns. It is observed that both local residents and inbound visitors have increased their leisure-oriented spending in Mainland China. Such market dynamics have led to a certain degree of pressure on Hong Kong's local market, which has exerted a moderate adverse effect on the Group's business development.

In 2026, the Group's customers are mainly sourced from Mainland China. However, the Chinese economy in 2026 remains challenging. This economic environment may affect the Group's business as customers' purchasing power and willingness to consume may be constrained. Faced with the challenges of the Chinese economy, the Group may need to adjust its business strategies to adapt to the changing environment and seek new opportunities to maintain a stable business growth.

The Group's business primarily comes from Mainland China and Hong Kong, focusing on medical and aesthetic medical services. Leveraging the opportunity presented by visitors to Hong Kong, the Group provides medical services in Hong Kong for customers from Mainland China, introducing premium, high-quality, and tailored medical aesthetic and value-added health services to meet their needs, thereby establishing a competitive industry service system. However, as a sustainable enterprise, the Group will continually assess the Company's business operations and development direction, offering more comprehensive solutions to cater to the diverse needs of consumers.

業務回顧及未來前景

於本中期回顧期內，香港與中國內地的跨境往來維持穩定。惟非必需消費領域的市場復甦步伐參差，受區內消費者審慎情緒影響，本集團業務並未取得預期增長，期內營運動力有所放緩。

儘管香港整體經營環境相對改善，惟受消費模式轉變，零售及服務行業持續面對經營壓力。市場可見，本地居民及訪港旅客將更多休閒類消費投放至中國內地。該等市場情況為香港本地市場帶來一定壓力，繼而對本集團的業務發展造成適度不利影響。

在二零二六年，本集團的客源主要來自中國內地。然而，二零二六年中國經濟仍然處於嚴峻的情況下。這種經濟環境可能對本集團的業務產生影響，因為客戶的購買力及消費意願可能受到限制。面對中國經濟的挑戰，本集團可能需要調整業務策略，以因應環境變化，並尋找新的機會來維持業務穩定發展。

本集團的業務主要來自中國內地及香港，專注於醫療及美學醫療服務。本集團透過訪港旅客的機遇，為來自內地的顧客提供本港的醫療服務，引入尊貴、優質及滿足彼等需求的醫療美容及增值健康服務，形成了具備市場競爭力的產業服務體系。不過，作為可持續發展的企業，本集團將持續評估公司的業務營運及發展方向，提供更完善的方案，以迎合不同消費者的需求。

FUTURE PROSPECT

The Group continues to strive for opportunity to widen its business scope in the healthcare industry and reallocate its resources when appropriate, to strengthen and maintain as one of the leading pioneers in the healthcare products and services sector.

FINANCIAL REVIEW

RESULTS

The Group recorded a revenue of approximately HK\$41.73 million for the six months ended 30 June 2026, representing an increase of 52.35% from the last period (six months ended 30 June 2025: HK\$27.39 million). Gross profit increased by 36.02% to approximately HK\$24.32 million from the last period (six months ended 30 June 2025: HK\$17.88 million). The Group recorded a profit before tax for the six months ended 30 June 2026 of approximately HK\$4.62 million (six months ended 30 June 2025: HK\$4.61 million).

The overall revenue growth was primarily driven by increased spending from customers from Mainland China, partially offset by softening local consumption sentiment within Hong Kong.

Total operating expenses of the Group for the six months ended 30 June 2026 was approximately HK\$20.12 million, representing an increase of 14.38% from the last period (six months ended 30 June 2025: HK\$17.59 million). The rise in operating costs was driven largely by higher staff costs and marketing expenses to support revenue expansion.

未來前景

本集團將繼續爭取擴大其於保健行業之業務範圍的機會，並適時重新分配其資源以加強和維持其在大健康產品及服務領域的領先地位。

財務回顧

業績

本集團錄得截至二零二六年六月三十日止六個月收益約41,730,000港元，較上一期間增加52.35%（截至二零二五年六月三十日止六個月：27,390,000港元）。毛利較上一期間增加36.02%至約24,320,000港元（截至二零二五年六月三十日止六個月：17,880,000港元）。本集團錄得截至二零二六年六月三十日止六個月除稅前溢利約4,620,000港元（截至二零二五年六月三十日止六個月：4,610,000港元）。

整體收益增長主要受中國內地客戶消費增加所帶動，惟部分被香港本地消費意欲轉弱所抵銷。

本集團截至二零二六年六月三十日止六個月之總營運開支約為20,120,000港元，較上一個期間增加14.38%（截至二零二五年六月三十日止六個月：17,590,000港元）。營運開支增加主要源於為擴充業務收益而增聘人手、加大市場推廣開支所致。

FINANCIAL REVIEW (Continued)

NET CURRENT ASSETS AND NET ASSETS

As at 30 June 2026, the Group recorded net current assets of approximately HK\$34.20 million (31 December 2025: HK\$10.81 million) and net assets of approximately HK\$56.76 million (31 December 2025: HK\$53.47 million). The increase of net current assets and net assets was mainly attributable to the profit for the six months ended 30 June 2026 from operations of approximately HK\$4.62 million. The Board will closely monitor the development and operation of the operating businesses and improve the financial position of the Group.

LIQUIDITY AND FINANCIAL RESOURCES

Cash and Bank Balances

As at 30 June 2026, the Group had cash and bank balances of approximately HK\$1.82 million of which approximately HK\$0.89 million were denominated in Hong Kong dollars.

Working Capital and Gearing Ratio

As at 30 June 2026, the Group had current assets of approximately HK\$94.59 million (31 December 2025: HK\$86.04 million), while its current liabilities was approximately HK\$60.39 million (31 December 2025: HK\$75.23 million), representing a net current assets position with a working capital ratio (current assets to current liabilities) of 1.57 (31 December 2025: 1.14).

As at 30 June 2026, the Group had no bank borrowings but shareholders' loans of approximately HK\$21.23 million (31 December 2025: HK\$30.11 million).

The gearing ratio of the Group as at 30 June 2026, calculated as shareholders' loans to total equity was 0.37 (31 December 2025: 0.56).

財務回顧 (續)

淨流動資產及淨資產

於二零二六年六月三十日，本集團錄得淨流動資產約34,200,000港元（二零二五年十二月三十一日：10,810,000港元）及淨資產約56,760,000港元（二零二五年十二月三十一日：53,470,000港元）。淨流動資產及淨資產的增加乃主要由於經營業務截至二零二六年六月三十日止六個月的溢利約4,620,000港元。董事會將密切監控經營業務的發展及運營並改善本集團的財務狀況。

流動資金及財務資源

現金及銀行結餘

於二零二六年六月三十日，本集團擁有現金及銀行結餘約1,820,000港元，其中約890,000港元以港元計值。

營運資金及資產負債比率

於二零二六年六月三十日，本集團流動資產約為94,590,000港元（二零二五年十二月三十一日：86,040,000港元），而流動負債約為60,390,000港元（二零二五年十二月三十一日：75,230,000港元），即處於淨流動資產狀況，而營運資金比率（流動資產比流動負債）為1.57（二零二五年十二月三十一日：1.14）。

於二零二六年六月三十日，本集團並無銀行借款，但有股東貸款約21,230,000港元（二零二五年十二月三十一日：30,110,000港元）。

本集團於二零二六年六月三十日按股東貸款與權益總額之比計算的資產負債比率為0.37（二零二五年十二月三十一日：0.56）。

FINANCIAL REVIEW (Continued)

TREASURY POLICY

The Group has adopted a prudent financial management approach towards its treasury policy. To manage the liquidity risk, the Board closely monitors the Group's liquidity position to ensure that the liquidity structure of the Group's assets, liabilities and other commitments can meet its funding requirements from time to time.

FOREIGN EXCHANGE EXPOSURE

The Group's business transactions, assets and liabilities are principally denominated in Renminbi and Hong Kong dollars. The Directors consider that the risk of foreign exchange exposure of the Group is manageable. The management will continue to monitor the foreign exchange exposure of the Group and is prepared to take prudent measures such as hedging when appropriate actions are required.

MATERIAL ACQUISITIONS AND DISPOSALS

Save as disclosed in this report, the Group had no material acquisitions or disposal of subsidiaries, associates and joint ventures during the six months ended 30 June 2026.

CAPITAL AND OTHER COMMITMENTS

As at 30 June 2026, the Group had no significant capital and other commitments.

SIGNIFICANT INVESTMENT HELD

Save for the Company's investment in various subsidiaries, the Group did not hold any significant investments as at 30 June 2026.

CHARGES ON ASSETS AND CONTINGENT LIABILITIES

As at 30 June 2026, the Group had no material charge of assets or contingent liabilities.

財務回顧 (續)

庫務政策

本集團就庫務政策採取審慎的財務管理策略。為管理流動資金風險，董事會密切監察本集團的流動資金狀況，以確保本集團的資產、負債及其他承擔的流動資金架構能滿足其不時的資金需要。

外匯風險

本集團的業務交易、資產及負債主要以人民幣及港元計值。董事認為本集團之外匯風險受控。管理層將繼續監控本集團的外匯風險，並於情況有需要時採取對沖等審慎措施。

重大收購及出售事項

除本報告所披露者外，本集團於截至二零二六年六月三十日止六個月概無重大收購或出售附屬公司、聯營公司及合營企業。

資本及其他承擔

於二零二六年六月三十日，本集團並無重大資本及其他承擔。

所持重大投資

除本公司於多間附屬公司的投資外，於二零二六年六月三十日，本集團並無持有任何重大投資。

資產抵押及或有負債

於二零二六年六月三十日，本集團並無重大資產抵押或或有負債。

FUTURE PLANS FOR MATERIAL INVESTMENT OR CAPITAL ASSETS

Saved as disclosed in this report, the Group did not have any concrete future plan for material investment or capital assets as at 30 June 2026.

DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

EMPLOYEE INFORMATION AND REMUNERATION POLICIES

As at 30 June 2026, the Group had 33 employees mainly located in Hong Kong and Mainland China (30 June 2025: 24 employees). As an equal opportunity employer, the Group's remuneration and bonus policies are determined with reference to the performance and experience of individual employees. The total amount of employee remuneration (including that of the Directors and retirement benefits scheme contributions) of the Group for the six months ended 30 June 2026 was approximately HK\$6.09 million (six months ended 30 June 2025: approximately HK\$6.30 million).

重大投資或資本資產未來計劃

除本報告所披露者外，於二零二六年六月三十日，本集團並無重大投資或資本資產之任何具體未來計劃。

股息

董事會並不建議派付截至二零二六年六月三十日止六個月之中期股息（截至二零二五年六月三十日止六個月：無）。

僱員資料及薪酬政策

於二零二六年六月三十日，本集團共有33名主要分佈於香港及中國內地的僱員（二零二五年六月三十日：24名僱員）。本集團為提供均等機會的僱主，其薪酬及獎金政策乃經參考僱員之個別表現及經驗而釐定。於截至二零二六年六月三十日止六個月，本集團之僱員薪酬總額（包括董事薪酬及退休福利計劃供款）約為6,090,000港元（截至二零二五年六月三十日止六個月：約為6,300,000港元）。

OTHER INFORMATION 其他資料

DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2026, the following Directors and chief executives of the Company had or were deemed to have interest or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules, related to securities transactions by the Directors to be notified to the Company and the Stock Exchange:

董事及最高行政人員 於股份及相關股份之 權益及淡倉

於二零二六年六月三十日，下列董事及本公司最高行政人員於本公司及其相聯法團（定義見香港法例第571章證券及期貨條例（「證券及期貨條例」）第XV部）之股份、相關股份或債券證中，擁有或被視作擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益或淡倉（包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉）；或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉；或(iii)根據GEM上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所之權益或淡倉：

LONG POSITIONS

Interests in the shares and underlying shares of the Company

好倉

於本公司股份及相關股份之權益

Name of Directors/ Chief executives	Capacity	Aggregate long position in the shares and underlying shares 於股份及相關 股份之好倉總計	Approximate percentage of the issued share capital 佔已發行股本 概約百分比
董事／最高行政人員姓名	身份		
Wang Chuang 王闖	Beneficial Owner 實益擁有人	73,875,530	24.28%
Leung Man Fai 梁文輝	Beneficial Owner 實益擁有人	31,000	0.01%

Save as disclosed above, as at 30 June 2026, none of the Directors nor the chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by Directors to be notified to the Company and the Stock Exchange.

除上文所披露者外，於二零二六年六月三十日，概無董事或本公司最高行政人員於本公司及其相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份或債券證中擁有或被視作擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益或淡倉（包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉）；或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉；或(iii)根據GEM上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所的權益或淡倉。

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES

LONG POSITIONS

Interests in the shares and underlying shares of the Company

主要股東及其他人士於股份及相關股份之權益

好倉

於本公司股份及相關股份之權益

Name of Shareholders	Capacity	Aggregate long position in the shares and underlying shares 於股份及相關股份之好倉總計	Approximate percentage of the issued share capital 佔已發行股本概約百分比
股東姓名／名稱	身份		
All Favour Holdings Limited (Note 1) 全輝控股有限公司 (附註1)	Beneficial owner 實益擁有人	58,254,776	19.15%
Arab Osman Mohammed (Note 1) 馬德民 (附註1)	Others 其他	58,342,276	19.18%
Wong Kwok Keung (Note 1) 黃國強 (附註1)	Others 其他	58,342,276	19.18%
Li Ren (Note 2) 李韜 (附註2)	Held by controlled corporation 由受控法團持有	58,254,776	19.15%
	Beneficial owner 實益擁有人	2,138,000	0.70%
Central Huijin Investment Ltd. (Note 3) 中央匯金投資有限責任公司 (附註3)	Held by controlled corporation 由受控法團持有	15,774,466	5.18%
Changzhou Yaoguang Enterprise Management Consulting Limited Liability Partnership* (Note 4) 常州市耀光企業管理諮詢合夥企業 (有限合夥) (附註4)	Held by controlled corporation 由受控法團持有	26,240,000	8.62%
Lei Changjuan (Note 4) 雷昌娟 (附註4)	Held by controlled corporation 由受控法團持有	26,240,000	8.62%
Changzhou Minxing Enterprise Management Consulting Services Limited Liability Partnership* (Note 5) 常州市中民星空企業管理諮詢服務合夥企業 (有限合夥) (附註5)	Held by controlled corporation 由受控法團持有	16,060,000	5.28%
Kong Yudong (Note 5) 孔玉東 (附註5)	Held by controlled corporation 由受控法團持有	16,060,000	5.28%

* For identification purpose only

* 僅供識別

1. All Favour Holdings Limited ("All Favour") is beneficially owned as to (i) 40% by Nat-Ace Wood Industry Ltd. ("Nat-Ace Wood Industry") and 20% by Honour Top Holdings Limited ("Honour Top"), of which Nat-Ace Wood Industry is ultimately and wholly-owned by Mr. Li Ren ("Mr. Li") and Honour Top is ultimately wholly owned by Mr. Dai Yumin ("Mr. Dai"), and (ii) 40% by Mr. Dai. Moreover, All Favour has been the beneficial owner of 58,254,776 shares. By virtue of the SFO, Mr. Dai, Mr. Li and Nat-Ace Wood Industry are deemed to be interested in 58,254,776 shares in which All Favour is interested in.

On 16 September 2015, Mr. Dai was granted 17,500,000 share options by the Company under the old share option scheme adopted by the Company on 14 September 2011 (the "Old Share Option Scheme") entitling him to subscribe for 17,500,000 shares at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Old Share Option Scheme. The number of shares to be issued upon full exercise of the said share options and the exercise price per share were adjusted to 875,000 shares and HK\$90.00 per share with effect from 16 May 2019 and 6 September 2023 respectively as a result of the twice share consolidation of the Company, details of which were disclosed in the announcements of the Company dated 15 May 2019 and 4 September 2023 respectively. Assuming the share options granted to Mr. Dai has been exercised in full, Mr. Dai shall hold an aggregate of 87,500 shares as beneficial owner. By virtue of the SFO, Mr. Dai, together with his deemed interests in All Favour, was deemed to be interested in an aggregate of 58,342,276 shares, representing approximately 19.18% of the issued share capital of the Company. All Favour has pledged its interests in 15,774,466 shares in favour of Optimus Prime Management Ltd. ("Optimus").

On 31 March 2022, a bankruptcy order was made against Mr. Dai. Subsequently, Messrs. Arab Osman Mohammed and Mr. Wong Kwok Keung were appointed as joint and several trustees (the "Trustees") of the property of Mr. Dai at the general meeting of creditors held on 6 May 2022. Accordingly, the property of Mr. Dai, including his shareholdings, shall vest in the Trustees pursuant to Section 58(2) of the Bankruptcy Ordinance (Cap. 6).

1. 全輝控股有限公司（「全輝」）由(i)邦強木業有限公司（「邦強木業」）實益擁有40%及Honour Top Holdings Limited（「Honour Top」）實益擁有20%，其中邦強木業由李韜先生（「李先生」）最終全資擁有，而Honour Top由戴昱敏先生（「戴先生」）最終全資擁有，及(ii)戴先生實益擁有40%。此外，全輝為58,254,776股股份之實益擁有人。根據證券及期貨條例，戴先生、李先生及邦強木業被視為於全輝擁有權益的58,254,776股股份中擁有權益。

於二零一五年九月十六日，戴先生獲本公司根據於二零一一年九月十四日採納的舊購股權計劃（「舊購股權計劃」）授予17,500,000份購股權，賦予其權利可按每股0.45港元之行使價認購17,500,000股股份，惟須遵守舊購股權計劃之條款及條件。本公司的兩次股份合併令於悉數行使上述購股權時將予發行之股份數目及每股行使價分別調整為875,000股股份及每股90.00港元，分別自二零一九年五月十六日及二零二三年九月六日起生效，有關詳情披露於本公司日期分別為二零一九年五月十五日及二零二三年九月四日之公告。假設授予戴先生之購股權獲悉數行使，戴先生將作為實益擁有人持有合共87,500股股份。根據證券及期貨條例，連同彼被視為於全輝擁有之權益，戴先生被視為於合共58,342,276股股份中擁有權益，佔本公司已發行股本約19.18%。全輝已將其於15,774,466股股份中的權益抵押予Optimus Prime Management Ltd.（「Optimus」）。

於二零二二年三月三十一日，戴先生獲發破產令。其後，於二零二二年五月六日舉行之債權人會議，馬德民先生及黃國強先生獲委任為戴先生財產之共同及個別受託人（「受託人」）。因此，根據第六章《破產條例》第58(2)條，戴先生之財產（包括其股權）須歸屬於受託人。

2. Mr. Li personally owns 2,138,000 shares. Mr. Li is therefore deemed to be interested in an aggregate of 60,392,776 shares, representing approximately 19.85% of the issued share capital of the Company.

3. Based on the disclosure of interests forms both filed on 14 December 2020 by China Orient Asset Management Co., Ltd ("COAMC") and China Orient Alternative Investment Fund ("COAIF"), Optimus has a security interest in 157,744,659 then shares of the Company. Optimus is wholly owned by COAIF. COAIF is wholly owned by China Orient Asset Management (International) Holding Limited ("COAMI"). COAMI is owned as to (i) 50% by Wise Leader Assets Ltd. ("Wise Leader") which is wholly owned by Dong Yin Development (Holdings) Limited ("Dong Yin"); and (ii) 50% by Dong Yin which is wholly owned by COAMC.

On 14 February 2025, Central Huijin Investment Ltd. ("Huijin") has been notified that all shares held by the Ministry of Finance of the PRC, representing approximately 71.55% of the total issued shares in COAMC will be assigned to Huijin. As a result, Huijin is deemed to be interested in 15,774,466 shares held by Optimus as security interest.

4. Changzhou Yaoguang Enterprise Management Consulting Limited Liability Partnership* ("Yaoguang") is a limited liability partnership established in the PRC and is managed by Ms. Lei Changjuan as the general partner and the shares were held by Yao Guang (Hong Kong) Enterprise Limited as nominee for Yaoguang. Accordingly, each of Yaoguang and Ms. Lei Changjuan is deemed to be interested in 26,240,000 shares.

2. 李先生個人擁有2,138,000股股份。故此，李先生被視為於合共60,392,776股股份中擁有權益，佔本公司已發行股本約19.85%。

3. 根據中國東方資產管理股份有限公司（「中國東方資產管理」）及China Orient Alternative Investment Fund（「COAIF」）所提交日期均為二零二零年十二月十四日之權益披露表格，Optimus於157,744,659股本公司當時股份中擁有抵押權益。Optimus由COAIF全資擁有，而COAIF由中國東方資產管理（國際）控股有限公司（「中國東方資產管理國際」）全資擁有。中國東方資產管理國際由：(i) Wise Leader Assets Ltd（「Wise Leader」）擁有50%權益，而Wise Leader由東銀發展（控股）有限公司（「東銀」）全資擁有；及(ii)東銀擁有50%權益，而東銀由中國東方資產管理全資擁有。

於二零二五年二月十四日，中央匯金投資有限責任公司（「匯金」）收到通知，中國財政部持有的所有股份（佔中國東方資產管理已發行股份總數的約71.55%）將劃轉予匯金。因此，匯金被視為於Optimus以抵押權益形式持有的15,774,466股股份中擁有權益。

4. 常州市耀光企業管理諮詢合夥企業（有限合夥）（「耀光」）為於中國成立之有限合夥企業，並由雷昌娟女士（作為普通合夥人）管理，股份由耀光（香港）企業有限公司（作為耀光的代名人）持有。因此，耀光及雷昌娟女士各自被視為於26,240,000股股份中擁有權益。

* For identification purpose only

* 僅供識別

5. Changzhou Minxing Enterprise Management Consulting Services Limited Liability Partnership* ("Minxing") is a limited liability partnership established in the PRC and is managed by Ms. Kong Yudong as the general partner and the shares were held by Zhong Min Starry (Hong Kong) Limited as nominee for Minxing. Accordingly, each of Minxing and Ms. Kong Yudong is deemed to be interested in 16,060,000 shares.

5. 常州市中民星空企業管理諮詢服務合夥企業(有限合夥) (「民星」) 為於中國成立之有限合夥企業，並由孔玉東女士(作為普通合夥人) 管理，股份由中民星空(香港)有限公司(作為民星的代名人) 持有。因此，民星及孔玉東女士各自被視為於16,060,000股股份中擁有權益。

Save as disclosed above, as at 30 June 2026, the Directors are not aware that there is any other party (other than the Directors and the chief executives of the Company) who had, or was deemed to have, interests or short positions in the shares, underlying shares and debentures of the Company (i) which would fall to be disclosed to the Company and Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or (ii) which were required, pursuant to Section 336 of the SFO, to be entered in the register referred to therein.

除上文所披露者外，於二零二六年六月三十日，董事概不知悉任何其他人士(董事及本公司最高行政人員除外)於本公司股份、相關股份及債券證中，擁有或被視作擁有(i)根據證券及期貨條例第XV部第2及3分部之條文須向本公司及聯交所披露之權益或淡倉；或(ii)根據證券及期貨條例第336條須記入該條所述登記冊內之權益或淡倉。

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed under the heading "DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES" above, at no time during the six months ended 30 June 2026, there were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Directors or chief executive of the Company or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company or its subsidiaries a party to any arrangements to enable the Directors, to acquire such rights or benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

董事收購股份或債券證之權利

除上文「董事及最高行政人員於股份及相關股份之權益及淡倉」一節所披露者外，截至二零二六年六月三十日止六個月任何時間，概無任何董事或本公司最高行政人員或彼等各自之配偶或未成年子女獲授或行使任何可透過購買本公司之股份或債權證而獲益之權利；本公司或其附屬公司亦無訂立任何安排，致使董事透過購買本公司或任何其他法人團體之股份或債權證獲得該等權利或利益。

DIRECTORS' INTEREST IN COMPETING BUSINESS

None of the Directors or the substantial shareholders of the Company, or any of their respective close associates (as defined under the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group during the six months ended 30 June 2026.

董事於競爭性業務之權益

於截至二零二六年六月三十日止六個月，概無任何董事或本公司主要股東或任何彼等各自之緊密聯繫人(定義見GEM上市規則)於與本集團業務構成競爭或可能構成競爭之業務中擁有任何權益。

* For identification purpose only

* 僅供識別

SHARE SCHEME

At the 2025 annual general meeting of the Company, the shareholders approved the adoption of the new share option scheme (the “New Share Option Scheme”) (i) to recognise the contributions by the eligible participants with an opportunity to acquire a proprietary interest in the Company; (ii) to encourage and retain such individuals for the continual operation and development of the Group; (iii) to provide additional incentives for them to achieve performance goals (if any); (iv) to attract suitable personnel for further development of the Group; and (v) to motivate the selected eligible participants to maximise the value of the Company for the benefits of both the eligible participants and the Company, with a view to achieving the objectives of increasing the value of the Group and aligning the interests of the eligible participants directly to the shareholders through ownership of shares. The New Share Option Scheme was adopted on 27 June 2025, being the date on which the New Share Option Scheme becomes unconditional. As at 30 June 2026, the total number of shares available for issue under the New Share Option Scheme was 30,425,248, representing 10% of the total issued shares of the Company (excluding treasury shares) as at the date of this interim report.

As at the date of this interim report, the New Share Option Scheme has a remaining term of approximately nine years.

No share options were granted under the New Share Option Scheme since its adoption. Accordingly, the number of options available for grant under the scheme mandate of the New Share Option Scheme as at 1 January 2026 and 30 June 2026 was 30,425,248 shares and the number of options available for grant under the service provider sublimit of the New Share Option Scheme was 3,042,524 shares, respectively.

The Company does not have any other share schemes except for the New Share Option Scheme, the number of shares that may be issued in respect of the share options granted as at 30 June 2026 divided by the weighted average number of issued shares of the Company for the six months ended 30 June 2026 was 0.

For details of the principal terms of the New Share Option Scheme, please refer to the Company’s circular dated 4 June 2025.

股份計劃

於本公司的二零二五年股東週年大會上，股東批准採納新購股權計劃（「新購股權計劃」），以(i)認可合資格參與者的貢獻，使其有機會獲得本公司的專有權益；(ii)鼓勵及挽留該等人士，以落實本集團的持續經營及發展；(iii)向彼等提供額外獎勵以實現業績目標（如有）；(iv)吸引合適人員，以實現本集團的進一步發展；及(v)激勵選定合資格參與者將本公司的價值最大化，使合資格參與者及本公司受益，以期實現提高本集團價值，及通過擁有股份使合資格參與者的利益直接與股東利益保持一致的目標。新購股權計劃於二零二五年六月二十七日（即新購股權計劃成為無條件之日）採納。於二零二六年六月三十日，根據新購股權計劃可予發行的股份總數為30,425,248股，於本中期報告日期佔本公司已發行股份總數（不包括庫存股份）的10%。

於本中期報告日期，新購股權計劃尚餘有效期約為九年。

自採納新購股權計劃以來，並無根據該計劃授予任何購股權。據此，於二零二六年一月一日及二零二六年六月三十日，根據新購股權計劃的計劃授權可供授出的購股權數目為30,425,248股股份，而根據新購股權計劃的服務供應商分項限額可供授出的購股權數目則為3,042,524股股份。

除新購股權計劃外，本公司並無任何其他股份計劃，就於二零二六年六月三十日授出購股權而言可能發行的股份數目除以本公司截至二零二六年六月三十日止六個月的已發行股份加權平均數為0。

有關新購股權計劃之主要條款的詳情，請參見本公司日期為二零二五年六月四日之通函。

ISSUE OF EQUITY SECURITIES OR SALE OF TREASURY SHARES

During the six months ended 30 June 2026, the Company did not issue any equity securities or sell any treasury shares.

CORPORATE GOVERNANCE PRACTICES

The Company has complied with all the code provisions as set out in the Corporate Governance Code as contained in part 2 of Appendix C1 of the GEM Listing Rules (the “CG Code”) throughout the six months ended 30 June 2026, except for the following deviation:

Under code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing. As Mr. Wang Chuang was appointed as both the chairman and the chief executive officer of the Company, such practice deviates from code provision C.2.1 of the CG Code. The Board believes that vesting the roles for both the chairman and the chief executive officer of the Company in the same person can facilitate the execution of the Group’s business strategies and boost effectiveness of its operation. Therefore, the Board considers that the deviation from code provision C.2.1 of the CG Code is appropriate in such circumstance. However, the Board will keep reviewing the current structure from time to time and appoint candidate with suitable knowledge, skill and experience as chairman or chief executive of the Company, if identified, to ensure compliance with the CG Code and align with the latest development.

發行股本證券或出售庫存股份

於截至二零二六年六月三十日止六個月，本公司並無發行任何股本證券或出售任何庫存股份。

企業管治常規

本公司截至二零二六年六月三十日止六個月已遵守GEM上市規則附錄C1第2部所載之企業管治守則（「企業管治守則」）之所有守則條文，惟以下偏離除外：

根據企業管治守則之守則條文第C.2.1條，主席和行政總裁的角色應有區分，不應由同一人同時兼任。主席與行政總裁之間的職責分工應以書面形式清楚訂明。由於王闖先生獲委任為本公司主席及行政總裁，該舉措偏離企業管治守則之守則條文第C.2.1條。董事會相信，將本公司主席及行政總裁的角色歸屬同一人，有助執行本集團的業務策略及提升其營運效率。因此，董事會認為在此情況下，偏離企業管治守則之守則條文第C.2.1條乃屬恰當。然而，董事會將不時繼續檢討現行架構，並委任具備合適知識、技能及經驗的候選人（倘能物色）為本公司主席或行政總裁，以確保遵守企業管治守則及與最新發展一致。

REVIEW OF INTERIM FINANCIAL STATEMENTS BY AUDIT COMMITTEE

The Audit Committee has three members, comprising of our independent non-executive Directors, namely Mr. Leung Man Fai (the chairman of the Audit Committee), Ms. Huo Chunyu and Mr. Zhou Xudong. The Company's unaudited condensed consolidated interim financial statements for the six months ended 30 June 2026 have been reviewed by the Audit Committee.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the required standard of dealings (the "Required Standard of Dealings") as set out in Rules 5.48 to 5.67 of the GEM Listing Rules as the code of conduct for dealing in securities of the Company by the Directors. Having made specific enquiry of all Directors, all of the Directors have confirmed that they have fully complied with the Required Standards of Dealings regarding securities transaction by the Directors as set out on the GEM Listing Rules throughout the six months ended 30 June 2026.

PURCHASE, SALE OR REDEMPTION OF SECURITIES

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including the sales of treasury shares).

As at 30 June 2026, the Company did not hold any treasury shares.

EVENT AFTER THE REPORTING PERIOD

There was no significant event occurred since 30 June 2026 and up to the date of this report.

審核委員會審閱中期財務報表

審核委員會有三位成員，包括我們獨立非執行董事，即梁文輝先生（審核委員會主席）、霍春玉女士及周旭東先生。審核委員會已審閱本公司截至二零二六年六月三十日止六個月之未經審核簡明綜合中期財務報表。

董事進行證券交易

本公司已採納GEM上市規則第5.48條至5.67條所載的交易規定準則（「交易規定準則」）作為董事買賣本公司證券之操守守則。經向全體董事作出特定查詢後，各董事已確認彼等於截至二零二六年六月三十日止六個月，已全面遵守載於GEM上市規則之董事進行證券交易之買賣規定標準。

購買、出售或贖回證券

於截至二零二六年六月三十日止六個月，本公司及其任何附屬公司概無購買、贖回或出售任何本公司上市證券（包括出售庫存股份）。

於二零二六年六月三十日，本公司未持有任何庫存股份。

報告期後事項

自二零二六年六月三十日起至本報告日期止，概無發生任何重大事件。

CHANGES TO BIOGRAPHICAL DETAILS OF DIRECTORS

Save as disclosed in this interim report, there has been no change in the information of Directors that is required to be disclosed under Rule 17.50A(1) of the GEM Listing Rules.

By Order of the Board

China Regenerative Medicine International Limited
Mr. Wang Chuang

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 21 August 2026

As at the date of this report, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Ms. Luo Min; and the independent non-executive Directors are Ms. Huo Chunyu, Mr. Zhou Xudong and Mr. Leung Man Fai.

This report will remain on the "Latest Listed Company Information" page of the GEM website at www.hkexnews.hk for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.

董事的履歷詳情變動

除本中期報告所披露者外，概無根據GEM上市規則第17.50A(1)條須披露的董事資料變動。

承董事會命

中國再生醫學國際有限公司
主席、行政總裁兼執行董事
王闖先生

香港，二零二六年八月二十一日

於本報告日期，執行董事為王闖先生（主席兼行政總裁）；非執行董事為雒敏女士；以及獨立非執行董事為霍春玉女士、周旭東先生及梁文輝先生。

本報告將由刊發日期起計至少保留七日於GEM網站www.hkexnews.hk之「最新上市公司公告」一頁及於本公司之網站www.crmi.hk內登載。